These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38936103)

  • 1. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.
    Pearson AD; DuBois SG; Macy ME; de Rojas T; Donoghue M; Weiner S; Knoderer H; Bernardi R; Buenger V; Canaud G; Cantley L; Chung J; Fox E; Friend J; Glade-Bender J; Gorbatchevsky I; Gore L; Gupta A; Hawkins DS; Juric D; Lang LA; Leach D; Liaw D; Lesa G; Ligas F; Lindberg G; Lindberg W; Ludwinski D; Marshall L; Mazar A; McDonough J; Nysom K; Ours C; Pappo A; Parsons DW; Rosenfeld A; Scobie N; Smith M; Taylor D; Weigel B; Weinstein A; Karres D; Vassal G
    Eur J Cancer; 2024 Aug; 207():114145. PubMed ID: 38936103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy.
    Wani AK; Singh R; Akhtar N; Prakash A; Nepovimova E; Oleksak P; Chrienova Z; Alomar S; Chopra C; Kuca K
    Mini Rev Med Chem; 2024; 24(16):1496-1520. PubMed ID: 38265369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
    Lauring J; Park BH; Wolff AC
    J Natl Compr Canc Netw; 2013 Jun; 11(6):670-8. PubMed ID: 23744866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
    Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
    Barrett D; Brown VI; Grupp SA; Teachey DT
    Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
    Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
    Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
    Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the PI3-kinase/Akt/mTOR signaling pathway.
    Hassan B; Akcakanat A; Holder AM; Meric-Bernstam F
    Surg Oncol Clin N Am; 2013 Oct; 22(4):641-64. PubMed ID: 24012393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
    Feldman ME; Shokat KM
    Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
    Janku F; Tsimberidou AM; Garrido-Laguna I; Wang X; Luthra R; Hong DS; Naing A; Falchook GS; Moroney JW; Piha-Paul SA; Wheler JJ; Moulder SL; Fu S; Kurzrock R
    Mol Cancer Ther; 2011 Mar; 10(3):558-65. PubMed ID: 21216929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.
    O' Neill C
    Exp Gerontol; 2013 Jul; 48(7):647-53. PubMed ID: 23470275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Allen C; Fangusaro J; Hutter C; Witt O; Weiner S; Reaman G; Russo M; Bandopadhayay P; Ahsan S; Barone A; Barry E; de Rojas T; Fisher M; Fox E; Bender JG; Gore L; Hargrave D; Hawkins D; Kreider B; Langseth AJ; Lesa G; Ligas F; Marotti M; Marshall LV; Nasri K; Norga K; Nysom K; Pappo A; Rossato G; Scobie N; Smith M; Stieglitz E; Weigel B; Weinstein A; Viana R; Karres D; Vassal G
    Eur J Cancer; 2022 Dec; 177():120-142. PubMed ID: 36335782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
    Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
    Janku F; Wheler JJ; Naing A; Falchook GS; Hong DS; Stepanek VM; Fu S; Piha-Paul SA; Lee JJ; Luthra R; Tsimberidou AM; Kurzrock R
    Cancer Res; 2013 Jan; 73(1):276-84. PubMed ID: 23066039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.
    Rafii S; Roda D; Geuna E; Jimenez B; Rihawi K; Capelan M; Yap TA; Molife LR; Kaye SB; de Bono JS; Banerji U
    Clin Cancer Res; 2015 Apr; 21(8):1869-76. PubMed ID: 25649020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
    Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
    Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
    Owonikoko TK; Khuri FR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.